triple combination therapy

AIDS Any 3-agent antiretroviral regimen—in developing nations, D4T, 3TC and nevirapine—to manage HIV-1 infection; in general, the use of multiple agents of different classes is thought to improve the probability of a positive outcome
Cardiology
(1) The use of 3 agents—e.g., ARBs, beta blockers and ACE inhibitors—to decrease morbidity and mortality in patients with congestive heart failure
(2) Triple antithrombotic therapy The simultaneous use of aspirin, clopidogrel and warfarin. No clots, copious bleeding
Fringe medicine A combination of herbs, yoga, meditation and diet to manage HIV-1+ patients
Gastroenterology A therapy that requires 3 modalities or agents—e.g., TT for H pylori infection includes a proton-pump inhibitor (e.g., omeprazole) and 2 antibiotics (e.g., amoxicillin, clarithromycin)
Hepatology A combination of Zadaxin®, pegylated IFN alpha and ribavirin, used to manage HPV C in nonresponders to IFN and ribavirin alone
Obstetrics The administration of low-dose aspirin, heparin, and prednisone in a habitual aborter with primary antiphospholipid syndrome at an increased risk of DVTs Note: Corticosteroids are ineffective in APS and increase maternal morbidity and foetal prematurity
Oncology—lung The use of 3 different chemotherapeutics—e.g., vinorelbine, gemcitabine, and carboplatin—in patients with non-small cell CA of lung
Oncology—lymphoma Alternating triple therapy The alternating of 3 different chemotherapy regimens—e.g., CHOP-MINE-ESHAP in lymphoma
Oncology—pancreas The use of 3 chemotherapeutics—e.g., gemcitabine, cisplatin, infused fluorouracil—in pancreatic cancer
Pulmonary medicine The use of 3 agents—inhaled corticosteroids, long-acting 2-agonists (e.g., salmeterol) and leukotriene modifiers (e.g., montelukast). Leukotrienes do not help in asthma
Transplantation A 3-agent immunosuppressant regimen—e.g., cyclosporine, azathioprine (or everolimus), and methylprednisolone—to minimize rejection in patients receiving lungs or other transplanted organs See Asthma
Urology The use of hormonal therapy, brachytherapy, and external beam radiation for local control in high-risk prostates See Prostate CA

triple combination therapy

AIDS See HAART.
References in periodicals archive ?
Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler.
M2 EQUITYBITES-January 30, 2018-AstraZeneca reveals top-line results from Phase III trial of PT010 triple combination therapy
M2 PHARMA-January 30, 2018-AstraZeneca reveals top-line results from Phase III trial of PT010 triple combination therapy
We administered a triple combination therapy with ceftriaxone, doxycycline, and rifampin to the patient and haemodialysis was initiated.
The fact that tezacaftor/ivacaftor will be the basis of triple combination therapy makes this positive data even more exciting for patients with CF and the physicians who care for them.
GlaxoSmithKline and Innoviva have filed a regulatory submission with the FDA for the once-daily, closed triple combination therapy fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI 100/62.
GlaxoSmithKline PLC (GSK) has filed a New Drug Application (NDA) with the Food and Drug Administration seeking approval for its once-daily, closed triple combination therapy for patients with chronic obstructive pulmonary disease (COPD).
True (A) or false (B)--click on the correct answer: The use of ddI and d4T in pregnancy as part of triple combination therapy regimens is not recommended due to increased risk of lipodystrophy.
InterMune reported that after 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts in the study, and was -5.
Women who received single-dose nevirapine at the time of childbirth had better outcomes from nevirapine-based triple combination therapy if they started ART more than 6 months after delivery, researchers in the USA report in the New England Journal of Medicine.
She recommended triple combination therapy with Tri-Luma as superior to each of these alone and in combination.
A paper published by Daniel Kuritzkes and colleagues in the Journal of Acquired Immune Deficiency Syndromes contributes to the body of evidence showing that dual NRTI therapy, although able to suppress virus for some patients for a limited duration, is not as strong as triple combination therapy in terms of keeping resistance at bay for the longest duration.